Wealthspire Advisors LLC Sells 2,493 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wealthspire Advisors LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 30.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,619 shares of the biopharmaceutical company’s stock after selling 2,493 shares during the quarter. Wealthspire Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $4,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Mizuho Securities USA LLC lifted its position in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after buying an additional 51,162 shares during the last quarter. Principal Financial Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares during the last quarter. Golden State Equity Partners lifted its position in Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 1,272 shares during the last quarter. Finally, Fagan Associates Inc. lifted its position in Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after buying an additional 3,832 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.6 %

REGN stock opened at $700.33 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The business’s 50-day moving average is $699.40 and its two-hundred day moving average is $881.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $76.56 billion, a price-to-earnings ratio of 18.29, a P/E/G ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Analyst Ratings Changes

REGN has been the topic of a number of analyst reports. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. TD Cowen decreased their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Finally, Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Get Our Latest Stock Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.